12 research outputs found
ΠΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΠΈΠΌΠΌΡΠ½Π½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
Introduction. Prostate cancer is by far the most frequently diagnosed cancer among the male population and ranks fifth in the world in terms of mortality rates among malignant neoplasms. Today it is known that the tumor microenvironment plays an important role in the pathogenesis of the disease. Abundant data has accumulated indicating that cells of the inflammatory infiltrate of the tumor are involved in the onset, progression and response to treatment in cases of prostate cancer. However, their role in the context of disease progression has not yet been determined. In this work, we studied the phenotype of inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients.The study objective is to determine the features of the inflammatory infiltrate of prostate cancer and its association with the clinical and morphological characteristics of patients with this disease.Materials and methods. The study included tumor samples obtained from 31 patients with prostate cancer. The expression of CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1, PD-L1 (programmed death-ligand 1) was assessed by immunohistochemistry. The relationship between markers and clinical and morphological characteristics was assessed using the nonparametric MannβWhitney test and Fisherβs exact test. Spearmanβs rank correlation coefficient was used to analyze the correlations between contents of cells of different phenotypes. Differences were considered statistically significant at p <0.05.Results. This study describes the features of the stroma of prostate cancer. We have shown that an increased content of CD204+ cells is associated with an older age of patients (p = 0.0026), and the number of CD163+ and CD8+ cells with no metastases to regional lymph nodes (p = 0.0067 and p = 0.0069, respectively). It has been shown that PU.1 can be used as a general marker of macrophages. We also found significant correlations between the level of PU.1 and PD-L1 in the stroma (r = 0.421; p = 0.018) and IDO1 in the stroma (r = 0.557; p = 0.001) and in tumor cells (r = 0.393; p = 0.029), CD68 with IDO1 in the stroma (r = 0.535; p = 0.002), CD163 with PD-L1 and IDO1 in the stroma (r = 0.399; p = 0.026 and r = 0.220; p = 0.026, respectively).Conclusion. In this work, the characteristics of the stroma of prostate cancer were investigated. Our data indicate that tumor associated macrophages are the main cells expressing PD-L1 and IDO1 in the tumor stroma in the case of prostate cancer. Increased expression of IDO1 in tumor tissue is associated with the immunosuppressive phenotype of the inflammatory infiltrate. The fact that the number of macrophages directly correlates with the number of T-lymphocytes in the prostate stroma, and the number of M2 macrophages with cytotoxic T-cells indicates the interaction of the mechanisms of innate and acquired immunity during the progression of prostate cancer.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°ΠΊ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΠ°ΡΡΠΎ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΡΠ΅ΠΌΡΠΌ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ ΡΡΠ΅Π΄ΠΈ ΠΌΡΠΆΡΠΊΠΎΠ³ΠΎ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΈ Π·Π°Π½ΠΈΠΌΠ°Π΅Ρ 5-Π΅ ΠΌΠ΅ΡΡΠΎ Π² ΠΌΠΈΡΠ΅ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΡΡΠ΅Π΄ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈΠ³ΡΠ°Π΅Ρ Π±ΠΎΠ»ΡΡΡΡ ΡΠΎΠ»Ρ Π² ΠΏΠ°ΡΠΎΠ³Π΅Π½Π΅Π·Π΅ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. ΠΠ°ΠΊΠΎΠΏΠ»Π΅Π½ΠΎ ΠΌΠ½ΠΎΠ³ΠΎ Π΄Π°Π½Π½ΡΡ
, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡΠΈΡ
ΠΎ ΡΠΎΠΌ, ΡΡΠΎ ΠΊΠ»Π΅ΡΠΊΠΈ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΡΡΠ°ΡΡΠ²ΡΡΡ Π² Π²ΠΎΠ·Π½ΠΈΠΊΠ½ΠΎΠ²Π΅Π½ΠΈΠΈ, ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ ΠΈ ΠΎΡΠ²Π΅ΡΠ΅ Π½Π° Π»Π΅ΡΠ΅Π½ΠΈΠ΅ Π² ΡΠ»ΡΡΠ°ΡΡ
ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΈΡ
ΡΠΎΠ»Ρ Π² ΠΊΠΎΠ½ΡΠ΅ΠΊΡΡΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ Π΅ΡΠ΅ Π½Π΅ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Π°. Π² ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»Π΅Π½ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ Π΅Π³ΠΎ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ².Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ° ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΠΈ Π΅Π³ΠΎ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π΄Π°Π½Π½ΡΠΌ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠ΅ΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 31 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ CD3, CD8, FoxP3, CD68, PU.1, CD204, CD163, IDO1 ΠΈ PD-L1 (Π»ΠΈΠ³Π°Π½Π΄Π° ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° ΠΏΡΠΎΠ³ΡΠ°ΠΌΠΌΠΈΡΡΠ΅ΠΌΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π³ΠΈΠ±Π΅Π»ΠΈ 1). ΠΠ»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ Π²Π·Π°ΠΈΠΌΠΎΡΠ²ΡΠ·ΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈΡΡ Π½Π΅ΠΏΠ°ΡΠ°ΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΌΠ°Π½Π½Π°βΠ£ΠΈΡΠ½ΠΈ ΠΈ ΡΠΎΡΠ½ΡΠΉ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΡΠΈΡΠ΅ΡΠ°. ΠΠ»Ρ Π°Π½Π°Π»ΠΈΠ·Π° ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ΠΌ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠ² ΠΏΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½Ρ ΡΠ°Π½Π³ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΠΏΠΈΡΠΌΠ΅Π½Π°. Π²ΠΎ Π²ΡΠ΅Ρ
Π°Π½Π°Π»ΠΈΠ·Π°Ρ
Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ p β€0,05 ΡΡΠΈΡΠ°Π»ΠΎΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. Π Ρ
ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½Ρ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΡΠ»ΠΎ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ CD204+-ΠΊΠ»Π΅ΡΠΎΠΊ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½ΠΎ Ρ Π±ΠΎΠ»Π΅Π΅ ΡΡΠ°ΡΡΠΈΠΌ Π²ΠΎΠ·ΡΠ°ΡΡΠΎΠΌ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² (Ρ = 0,0026), Π° ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ CD163+- ΠΈ CD8+-ΠΊΠ»Π΅ΡΠΎΠΊ β Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² Π² ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΠ΅ Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠ·Π»Ρ (Ρ = 0,0067 ΠΈ Ρ = 0,0069 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ). ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ PU.1 ΠΌΠΎΠΆΠ΅Ρ Π±ΡΡΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ ΠΊΠ°ΠΊ ΠΎΠ±ΡΠΈΠΉ ΠΌΠ°ΡΠΊΠ΅Ρ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ². Π’Π°ΠΊΠΆΠ΅ ΠΌΡ Π²ΡΡΠ²ΠΈΠ»ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ ΡΡΠΎΠ²Π½Ρ PU.1 Ρ PD-L1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,421; Ρ = 0,018), IDO1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,557; p = 0,001) ΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
(r = 0,393; Ρ = 0,029), Π° ΡΠ°ΠΊΠΆΠ΅ CD68 c IDO1 (r = 0,535; p = 0,002) ΠΈ ΡD163 c PDL1 ΠΈ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ (r = 0,399; p = 0,026 ΠΈ r = 0,220; p = 0,026 ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠ»ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΡΡΡΠΎΠΌΡ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ. ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ ΡΠΊΠ°Π·ΡΠ²Π°ΡΡ Π½Π° ΡΠΎ, ΡΡΠΎ ΠΎΡΠ½ΠΎΠ²Π½ΡΠΌΠΈ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠΈΠΌΠΈ PD-L1 ΠΈ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ, Π² ΡΠ»ΡΡΠ°Π΅ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ²Π»ΡΡΡΡΡ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, ΠΈΠ½ΡΠΈΠ»ΡΡΡΠΈΡΡΡΡΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»Ρ. ΠΠΎΠ²ΡΡΠ΅Π½Π½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ IDO1 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ Π²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΈΠ»ΡΡΡΠ°ΡΠ°. ΡΠΎΡ ΡΠ°ΠΊΡ, ΡΡΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² ΠΏΡΡΠΌΠΎ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎΠΌ Ρ-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² Π² ΡΡΡΠΎΠΌΠ΅ ΡΠ°ΠΊΠ° ΠΏΡΠ΅Π΄ΡΡΠ°ΡΠ΅Π»ΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ, Π° ΡΡΠΎΠ²Π΅Π½Ρ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² 2-Π³ΠΎ ΡΠΈΠΏΠ° β Ρ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ-ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ, ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΠ΅Ρ ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΈ ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π²ΡΠΎΠΆΠ΄Π΅Π½Π½ΠΎΠ³ΠΎ ΠΈ ΠΏΡΠΈΠΎΠ±ΡΠ΅ΡΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° Π² ΠΏΡΠΎΡΠ΅ΡΡΠ΅ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ
ΠΠ΅Π»ΠΊΠΈ sPD-1/sPD-L1 ΠΏΡΠΈ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°
Background. Implementation of immunotherapy in clinical oncological practice has significantly improved the results of cancer treatment. It resulted in the need for seeking new markers to assess the effectiveness of therapy and the disease prognosis.Aim. To analyze the content of soluble forms of PD-1 and PD-L1 immune checkpoint proteins in the blood serum of patients with non-small cell lung cancer and esophageal squamous cell carcinoma and their association with clinical and morphological characteristics of the disease and the disease prognosis.Materials and methods. The study included tumor samples obtained from 43 patients with non-small cell lung cancer and 21 patients with esophageal squamous cell carcinoma. The concentration of sPD-L1 and sPD-1 in the blood serum was determined using enzyme-linked immunosorbent assay (ELISA). The Mann β Whitney test was used to determine statistically significant differences in independent groups. A correlation analysis was performed using the Spearmanβs rank correlation coefficient. Overall survival was analyzed by constructing survival curves using the Kaplan β Meier method and a Cox proportional hazards model. The differences were considered statistically significant at p < 0.05.Results. The study showed that sPD-1 and sPD-L1 were found in the blood serum of both cancer patients and healthy donors, and their concentrations did not differ significantly. It was shown that the high concentration of sPD-L1 in the blood serum of patients with non-small cell lung cancer was significantly associated with the late stage of the disease and was an independent unfavorable prognostic factor. It should be noted that for patients with esophageal cancer, an unfavorable prognostic marker was the high concentration of the soluble form of PD-1 protein, and not PD-L1 ligand, as in case of lung cancer.Conclusion. The content of sPD-1 and sPD-L1 in the blood serum can have different prognostic significance for various types of cancer, and further studies are required to confirm their clinical usability.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΊΡΠΈΠ²Π½ΠΎΠ΅ Π²Π½Π΅Π΄ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΡΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΡΡ ΠΏΡΠ°ΠΊΡΠΈΠΊΡ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ»ΡΡΡΠΈΡΡ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΠΎΠ³ΠΎ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ. ΠΡΠΎ ΠΏΡΠΈΠ²Π΅Π»ΠΎ ΠΊ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠΈΡΠΊΠ° Π½ΠΎΠ²ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ², Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΡΠΎΡΡΡ
ΠΌΠΎΠΆΠ½ΠΎ ΠΎΡΠ΅Π½ΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠΌΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β Π°Π½Π°Π»ΠΈΠ· ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΡΡ
ΡΠΎΡΠΌ Π±Π΅Π»ΠΊΠΎΠ² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΈΠΌΠΌΡΠ½ΠΈΡΠ΅ΡΠ° sPD-1 ΠΈ PD-L1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡ
Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΎΡ 43 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ 21 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ° Ρ ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°. ΠΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ sPD-L1 ΠΈ sPD-1 ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ»ΠΈ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°. ΠΠ»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΡ
ΡΠ°Π·Π»ΠΈΡΠΈΠΉ Π² Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΡ
Π³ΡΡΠΏΠΏΠ°Ρ
ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π° β Π£ΠΈΡΠ½ΠΈ. ΠΠΎΡΡΠ΅Π»ΡΡΠΈΠΎΠ½Π½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΠ° ΡΠ°Π½Π³ΠΎΠ²ΠΎΠΉ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΠΈ Π‘ΠΏΠΈΡΠΌΠ΅Π½Π°. ΠΠ½Π°Π»ΠΈΠ· ΠΎΠ±ΡΠ΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ β ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
Π΄ΠΎΠΆΠΈΡΠΈΡ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΠ°ΠΏΠ»Π°Π½Π° β ΠΠ΅ΠΉΠ΅ΡΠ° ΠΈ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΎΠ΄Π΅Π»ΠΈ ΠΏΡΠΎΠΏΠΎΡΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ
ΡΠΈΡΠΊΠΎΠ² ΠΠΎΠΊΡΠ°. Π‘ΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠΌΠΈ ΡΡΠΈΡΠ°Π»ΠΈΡΡ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΏΡΠΈ Ρ < 0,05.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ sPD-1ΠΈ sPD-L1 ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°ΡΡΡΡ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ ΠΊΠ°ΠΊ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ, ΡΠ°ΠΊ ΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ², ΠΈ ΠΈΡ
ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π²ΡΡΠΎΠΊΠ°Ρ ΠΊΠΎΠ½ΡΠ΅Π½ΡΡΠ°ΡΠΈΡ sPD-L1 Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΏΠΎΠ·Π΄Π½Π΅ΠΉ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π΅Π·Π°Π²ΠΈΡΠΈΠΌΡΠΌ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΎΡΠΌΠ΅ΡΠΈΡΡ, ΡΡΠΎ Π΄Π»Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ ΡΠ²Π»ΡΠ΅ΡΡΡ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΡΠΎΡΠΌΡ ΡΠ΅ΡΠ΅ΠΏΡΠΎΡΠ° PD-1, Π° Π½Π΅ Π΅Π³ΠΎ Π»ΠΈΠ³Π°Π½Π΄Π° PD-L1, ΠΊΠ°ΠΊ Π΄Π»Ρ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ.ΠΡΠ²ΠΎΠ΄Ρ. Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ Π² ΡΡΠ²ΠΎΡΠΎΡΠΊΠ΅ ΠΊΡΠΎΠ²ΠΈ sPD-1ΠΈ sPD-L1 ΠΌΠΎΠΆΠ΅Ρ ΠΈΠΌΠ΅ΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ΅ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ Π΄Π»Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π½ΠΎΠ·ΠΎΠ»ΠΎΠ³ΠΈΠΉ, ΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ Π΅Π³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° Π΄Π»Ρ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠ΅Π±ΡΠ΅Ρ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠ΅Π³ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ
ΠΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΡΡΡΠΎΠΌΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΡΠΈΠΏΠΎΠ²
Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½Π°Ρ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΠ° ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅Ρ ΡΠΎΠ±ΠΎΠΉ Π³Π΅ΡΠ΅ΡΠΎΠ³Π΅Π½Π½ΡΡ Π³ΡΡΠΏΠΏΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡΡΡ Π²ΡΡΠΎΠΊΠΎΠΉ Π²Π°ΡΠΊΡΠ»ΡΡΠΈΠ·ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΡΡΡΡ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ. ΠΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΡΠΎΠ²Π΅ΡΡΠΈΠ»Π° ΠΏΡΠΎΡΡΠ² Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎΡΡΡ Π²ΡΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² Π΅Π΅ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ Π½Π΅ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ Π΄ΠΎΠ±ΠΈΡΡΡΡ Π΅ΡΠ΅ Π±ΠΎΠ»ΡΡΠΈΡ
ΡΡΠΏΠ΅Ρ
ΠΎΠ². ΠΠ·Π²Π΅ΡΡΠ½ΠΎ, ΡΡΠΎ Π² ΡΡΠΏΠ΅Ρ
Π΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π½Π΅ΠΌΠ°Π»ΠΎΠ²Π°ΠΆΠ½ΡΡ ΡΠΎΠ»Ρ ΠΈΠ³ΡΠ°Π΅Ρ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²Π°Ρ ΡΡΡΠΎΠΌΠ°. Π‘ΡΠ΅Π΄ΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΡΡΠΎΠΌΠ° ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ Π²Π°ΡΠΈΠ°Π½ΡΠ° ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΈΠ·ΡΡΠ΅Π½Π° Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ. ΠΠ΄Π½Π°ΠΊΠΎ ΠΎΡΡΠ°Π»ΡΠ½ΡΠ΅ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΡΠΈΠΏΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ Π½Π΅ ΠΈΠ·ΡΡΠ΅Π½Ρ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΠΏΠΈΡΠ°Π½ΠΈΠ΅ ΠΈΠΌΠΌΡΠ½ΠΎΡΡΠΏΡΠ΅ΡΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ° ΡΡΡΠΎΠΌΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ². ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 44 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠΎΡΠ΅ΡΠ½ΠΎ-ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² (16 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ, 15 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΠΈ 13 ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΎΡΠΊΠΈ). Π ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΡΡΠΎΠΌΡ, Π° ΠΈΠΌΠ΅Π½Π½ΠΎ CD68, CD206, PU.1, CD3, IDO1 ΠΈ PD-L1.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠ½Π°Π»ΠΈΠ· ΠΎΠ±ΡΠ΅Π³ΠΎ ΡΠΈΡΠ»Π° ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ², Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ, ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ Π½Π°ΠΈΠΌΠ΅Π½ΡΡΠ΅Π΅ ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΎΡΠΊΠΈ, Π² ΡΠΎ Π²ΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅. ΠΠ»Ρ Π’-ΠΊΠ»Π΅ΡΠΎΠΊ ΠΎΡΠΌΠ΅ΡΠ΅Π½Π° ΠΏΠΎΡ
ΠΎΠΆΠ°Ρ ΡΠΈΡΡΠ°ΡΠΈΡ: Π½Π°ΠΈΠ±ΠΎΠ»ΡΡΠ΅Π΅ ΡΠΈΡΠ»ΠΎ CD3+-ΠΊΠ»Π΅ΡΠΎΠΊ Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ Π² ΡΠ²Π΅ΡΠ»ΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
. Π Ρ
ΡΠΎΠΌΠΎΡΠΎΠ±Π½ΡΡ
ΠΈ ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΡΡ
ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΠΈΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΡΠ½ΠΈΠΆΠ΅Π½ΠΎ. Π’Π°ΠΊΠΆΠ΅ ΠΏΠ°ΠΏΠΈΠ»Π»ΡΡΠ½ΡΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΡΡ ΠΏΡΠ°ΠΊΡΠΈΡΠ΅ΡΠΊΠΈ ΠΏΠΎΠ»Π½ΡΠΌ ΠΎΡΡΡΡΡΡΠ²ΠΈΠ΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ PD-L1 ΠΈ IDO1 ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ Π΄ΡΡΠ³ΠΈΠΌΠΈ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ ΡΠΈΠΏΠ°ΠΌΠΈ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ ΠΏΠΎΡΠΊΠΈ. Π’Π°ΠΊΠΆΠ΅ ΠΌΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ Π΄Π»Ρ PU.1 Π½Π°Π±Π»ΡΠ΄Π°Π΅ΡΡΡ ΡΠΈΠ»ΡΠ½Π°Ρ ΠΏΠΎΠ»ΠΎΠΆΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΠΊΠΎΡΡΠ΅Π»ΡΡΠΈΡ Π΅Π³ΠΎ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²Π° Ρ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ, ΠΊΠ°ΠΊ ΠΈ Π΄Π»Ρ CD68. Π’Π°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, PU.1 ΠΌΠΎΠΆΠ½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΎΠ±ΡΠ΅Π³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° Π΄Π»Ρ ΠΎΠΏΠΈΡΠ°Π½ΠΈΡ ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² Π² ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΠΏΠΎΡΠΊΠΈ.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΈ, ΡΡΠΎ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΏΠΎΡΠΊΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠΈΠΏΠΎΠ² ΡΠΈΠ»ΡΠ½ΠΎ ΠΈ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΏΠΎ ΡΠΎΡΡΠ°Π²Ρ ΡΠ²ΠΎΠ΅Π³ΠΎ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ. ΠΡΠΎ, Π½Π΅ΡΠΎΠΌΠ½Π΅Π½Π½ΠΎ, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΡΡΠΈΡΡΠ²Π°ΡΡ ΠΏΡΠΈ Π²ΡΠ±ΠΎΡΠ΅ ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π² Π»Π΅ΡΠ΅Π½ΠΈΠΈ Π΄Π°Π½Π½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
Value orientations of the student youth in religious and secular universities
The article presents the results of the factor analysis applied to the data of mass survey on the value orientations of the students of secular and religious universities - Moscow Orthodox Theological Academy and Seminary, Lomonosov Moscow State University and Saint Petersburg State University. First, the authors provide a brief overview of the current state of sociological studies of values and value orientations of the youth and Russians with an emphasis on cross-cultural and other comparative contexts, which are so popular today. The article also considers different emphases in the sociological interpretation of the concepts of values and value orientations on the theoretical and empirical levels including the historical perspective. Since the research project consisted of several stages so as to solve a number of tasks and used different formats of the questionnaire for different samples (administration, professors and students), the article presents only a small part of the project designed to reveal the value orientations of students of secular and religious universities with the help of S. Schwartz and B. Bilski technique. The authors used this technique to identify similarities and differences in values and motives of students of secular and religious universities; suggest four factorial types of motivation; offer an interpretation of the observed factors and their manifestations in different student subsamples, such as the different circumstances of life of students in secular and religious universities and the more βexpertβ status of the latter in the (Christian, Orthodox) moral discourse, unlike the majority of students of secular universities, who can hardly be considered experts in secular ethics
Gd3+-Doped Magnetic Nanoparticles for Biomedical Applications
Magnetic nanoparticles (MNPs) made of iron oxides with cubic symmetry (Fe3O4, Ξ³-Fe2O3) are demanded objects for multipurpose in biomedical applications as contrast agents for magnetic resonance imaging, magnetically driven carriers for drug delivery, and heaters in hyperthermia cancer treatment. An optimum balance between the right particle size and good magnetic response can be reached by a selection of a synthesis method and by doping with rare earth elements. Here, we present a microwave-assisted polyol synthesis of iron oxide MNPs with actual gadolinium (III) doping from 0.5 to 5.1βmol.%. The resulting MNPs have an average size of 14βnm with narrow size distribution. Their surface was covered by a glycol layer, which prevents aggregation and improves biocompatibility. The magnetic hyperthermia test was performed on 1 and 2βmg/ml aqueous colloidal solutions of MNPs and demonstrated their ability to rise the temperature by 3Β°C during a 20β30βmin run. Therefore, the obtained Gd3+ MNPs are the promising material for biomedicine
Immunosuppressive peculiarities of stromal cells of various kidney tumor types
Background. Renal cell carcinoma is a heterogeneous group of tumors characterized by high vascularization and immunogenicity. Immunotherapy has made a breakthrough in the treatment of this pathology, however, the lack of development of criteria for its use does not allow to achieve even greater success. It is known that the tumor stroma plays an important role in the success of immunotherapy. Among the various histological types of kidney tumors, the stroma of the clear cell renal cell carcinoma has been studied in sufficient detail. However, the remaining histological types are practically not studied.Objective: description of the immunosuppressive phenotype of the stroma of kidney tumors of various histological types.Materials and methods. The study included tumor samples obtainedfrom 44patients with renal cell carcinoma of various histological types (16 samples of chromophobe cancer, 15 samples of clear cell and 13 samples of papillary renal cell carcinoma). The method of immunohis-tochemistry evaluated the expression of tumor stromal markers, namely CD68, CD206, PU.1, CD3, IDO1 and PD-L1 in the studied samples.Results. Analysis of the total number of macrophages associated with the tumor showed that the smallest number is observed in samples of chromophobe renal cancer, while in the samples of clear cell cancer their number is greatest. A similar situation is observed for T-cells: the largest number of CD3+ cells is observed in clear cell tumors. In chromophobe and papillary tumors, their number is reduced. Papillary tumors are also characterized by an almost complete absence of expression of PD-L1 and IDO1 compared to other histological types of kidney tumors. We also showed that for PU.1 there is a strong positive correlation between its quantity and localization, as in CD68. Thus, PU.1 can be used as a general marker for describing stromal macrophages in kidney tumors.Conclusion. The study showed that kidney tumors of various histological types strongly and significantly differ in the composition of their microenvironment. These data, of course, must be considered when choosing immune therapy in the treatment of this pathology
ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΠΎΠΉ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ki-67, ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ ΠΎΠ»ΠΈ Ξ±, CD20 ΠΈ CD31 ΠΏΡΠΈ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΌ ΡΠ°ΠΊΠ΅ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ
Introduction. Non-small cell lung cancer is a common cancer with a poor prognosis. Modern researchers conduct many studies devoted to understanding the molecular mechanisms of its pathogenesis. Modern advances in immunotherapy have significantly improved the prognosis of patients with this pathology, but this is still not enough to control the course of the disease.Objective β to the study of tumor (Ki-67, tumor necrosis factor Ξ± (TNF-Ξ±)) and stromal (TNF-Ξ±, CD20 and CD31) markers in non-small cell lung cancer and their prognostic significance.Materials and methods. The study included tumor samples obtained from 100 patients with non-small cell lung cancer. The expression of Ki-67, TNF-Ξ±, CD20 and CD31 was assessed by immunohistochemistry. Survival analysis was carried out by constructing survival curves using the KaplanβMeier method. To analyze the association of the expression of studied markers with clinical and morphological characteristics, the MannβWhitney test was used. Differences were considered statistically significant at p <0.05.Results. We analyzed the expression of Ki-67, TNF-Ξ±, CD20 and CD31 in non-small cell lung cancer tumors. Ki-67 expression was detected in tumor cells in 99 % of the samples studied and was not observed in stromal cells. In tumor and stromal cells, TNF-Ξ± expression was detected in 100 % of the samples. CD31 positive cells were also found in all samples studied, and CD20+B cells were present in 95 % of cases. TNF-Ξ± expression in tumor cells and tumor stroma is not associated with clinical and morphological characteristics. For the expression of CD20 in the tumor stroma, there was an association with tumor localization (p = 0.0435), with the stage of the disease (p = 0.0044), tumor size (p = 0.0017), and the presence of regional metastases (p = 0.0071). For Ki-67, there was a strong association with the histological type of tumor (p <0.0001), its localization (p = 0.0012) and the presence of regional metastases (p = 0.0020). The analysis of prognostic significance showed that TNF-Ξ± expression in tumor stroma cells is a favorable prognostic factor (hazard ratio 0.5547; p = 0.0139), while a high content of CD31+ cells is a factor of poor prognosis (hazard ratio 2.335; p = 0.0355). Next, we carried out a comprehensive analysis of the prognostic significance of the two identified markers simultaneously. It turned out that their combination of TNF-Ξ±/stroma (high expression)+CD31 (low expression) is a much more significant prognostic factor, in contrast to the individual analysis (hazard ratio 0.1966; p = 0.0048).Conclusion. The study showed that a complex rather than an individual assessment of the predictive value of several markers simultaneously more effectively reflects their predictive ability.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠ΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΉ ΡΠ°ΠΊ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½Π½ΠΎΠΉ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠ΅ΠΉ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΡΡΡΠ΅ΠΉΡΡ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΠ·ΠΎΠΌ. Π‘Π΅Π³ΠΎΠ΄Π½Ρ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΡΡΡ Π±ΠΎΠ»ΡΡΠΎΠ΅ ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ, ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π½ΡΡ
ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ. Π‘ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΠ΅ ΡΡΠΏΠ΅Ρ
ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎ ΡΠ»ΡΡΡΠΈΠ»ΠΈ ΠΏΡΠΎΠ³Π½ΠΎΠ· ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ, ΠΎΠ΄Π½Π°ΠΊΠΎ Π΄Π»Ρ ΠΊΠΎΠ½ΡΡΠΎΠ»Ρ Π½Π°Π΄ Π΅Π³ΠΎ ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ΠΌ ΡΡΠΎΠ³ΠΎ ΠΏΠΎΠΊΠ° Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
(Ki-67, ΡΠ°ΠΊΡΠΎΡ Π½Π΅ΠΊΡΠΎΠ·Π° ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Ξ± (TNF-Ξ±)) ΠΈ ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
(TNF-Ξ±, CD20 ΠΈ CD31) ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΈ ΠΈΡ
ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 100 Π±ΠΎΠ»ΡΠ½ΡΡ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ki-67, TNF-Ξ±, CD20 ΠΈ CD31. ΠΠ½Π°Π»ΠΈΠ· Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΎΠ±ΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
Π΄ΠΎΠΆΠΈΡΠΈΡ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΠ°ΠΏΠ»Π°Π½Π°βΠΠ°ΠΉΠ΅ΡΠ°. ΠΠ»Ρ ΠΎΡΠ΅Π½ΠΊΠΈ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΊΡΠΈΡΠ΅ΡΠΈΠΉ ΠΠ°Π½Π½Π°βΠ£ΠΈΡΠ½ΠΈ. Π Π°Π·Π»ΠΈΡΠΈΡ ΡΡΠΈΡΠ°Π»ΠΈΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΠΏΡΠΈ p <0,05.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΡ ΠΏΡΠΎΠ²Π΅Π»ΠΈ Π°Π½Π°Π»ΠΈΠ· ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ki-67, TNF-Ξ±, CD20 ΠΈ CD31 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π½Π΅ΠΌΠ΅Π»ΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° Π»Π΅Π³ΠΊΠΎΠ³ΠΎ. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Ki-67 ΠΎΠ±Π½Π°ΡΡΠΆΠΈΠ²Π°Π»Π°ΡΡ Π² 99 % ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΈ Π½Π΅ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΡΡΡΠΎΠΌΡ. Π ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΈ ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ TNF-Ξ± Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ Π² 100 % ΠΎΠ±ΡΠ°Π·ΡΠΎΠ². CD31+-ΠΊΠ»Π΅ΡΠΊΠΈ Π±ΡΠ»ΠΈ ΡΠ°ΠΊΠΆΠ΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Ρ Π²ΠΎ Π²ΡΠ΅Ρ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ
, Π° CD20+-B-ΠΊΠ»Π΅ΡΠΊΠΈ ΠΏΡΠΈΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ Π² 95 % ΡΠ»ΡΡΠ°Π΅Π². ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ TNF-Ξ± Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΈ ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π½Π΅ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ. Π ΡΠ»ΡΡΠ°Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD20 Π² ΡΡΡΠΎΠΌΠ΅ Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ c Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (p = 0,0435), ΡΠΎ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (p = 0,0044), ΡΠ°Π·ΠΌΠ΅ΡΠΎΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (p = 0,0017) ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² (p = 0,0071). Π ΡΠ»ΡΡΠ°Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ki-67 Π½Π°Π±Π»ΡΠ΄Π°Π»Π°ΡΡ ΡΠΈΠ»ΡΠ½Π°Ρ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ Ρ Π³ΠΈΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠΈΠΏΠΎΠΌ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (p <0,0001), Π΅Π΅ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΠ΅ΠΉ (p = 0,0012) ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² (p = 0,0020). ΠΠ½Π°Π»ΠΈΠ· ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΏΠΎΠΊΠ°Π·Π°Π», ΡΡΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ TNF-Ξ± Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ ΡΡΡΠΎΠΌΡ ΡΠ²Π»ΡΠ΅ΡΡΡ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² (ΠΠ ) 0,5547; p = 0,0139), Π² ΡΠΎ Π²ΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ Π²ΡΡΠΎΠΊΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ CD31+-ΠΊΠ»Π΅ΡΠΎΠΊ β ΡΠ°ΠΊΡΠΎΡΠΎΠΌ Π½Π΅Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² 2,335; p = 0,0355). ΠΠ°ΡΠ΅ΠΌ ΠΌΡ ΠΏΡΠΎΠ²Π΅Π»ΠΈ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½Π°ΡΠΈΠΈ 2 Π²ΡΡΠ²Π»Π΅Π½Π½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ². ΠΠΊΠ°Π·Π°Π»ΠΎΡΡ, ΡΡΠΎ ΡΠΎΡΠ΅ΡΠ°Π½ΠΈΠ΅ TNF-Ξ±/ΡΡΡΠΎΠΌΠ° (Π²ΡΡΠΎΠΊΠ°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ)+CD31 (Π½ΠΈΠ·ΠΊΠ°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ) ΡΠ²Π»ΡΠ΅ΡΡΡ Π½Π°ΠΌΠ½ΠΎΠ³ΠΎ Π±ΠΎΠ»Π΅Π΅ Π·Π½Π°ΡΠΈΠΌΡΠΌ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΡΠ°ΠΊΡΠΎΡΠΎΠΌ, Π² ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π°Β (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² 0,1966; p = 0,0048).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. ΠΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΠΊΠ°Π·Π°Π»ΠΎ, ΡΡΠΎ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½Π°Ρ, Π° Π½Π΅ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½Π°Ρ ΠΎΡΠ΅Π½ΠΊΠ° ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ ΠΎΠ΄Π½ΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΎΡΡΠ°ΠΆΠ°Π΅Ρ ΠΈΡ
ΠΏΡΠ΅Π΄ΠΈΠΊΡΠΈΠ²Π½ΡΡ ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ
ΠΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD204 ΠΈ IDO1 Π² ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°
Introduction. Cancer of the esophagus ranks sixth in mortality among malignant neoplastic diseases. To understand the molecular mechanisms of its progression, it is necessary to study not only tumor cells directly, but also cells of the microenvironment. In this work, we studied tumor-associated macrophages and their different phenotypes using membrane protein, indoleamine 2,3βdioxygenase-1 (IDO1) as a marker for type 1 macrophages and macrophage scavenger receptor (CD204) as a marker for type 2 macrophages.The objective of this work was to study the expression of IDO1 and CD204 in tumors of squamous cell carcinoma of the esophagus and to assess its prognostic value.Materials and methods. The study included tumor samples obtained from 48 patients with squamous cell carcinoma of the esophagus. The expression of CD204 and IDO1 was assessed by immunohistochemistry. Survival analysis was carried out by constructing survival curves using the KaplanβMeier method. Comparison of the significance of differences was performed using the logarithmic rank test. Differences were considered statistically significant at p <0.05.Results. We analyzed the expression of CD204 and IDO1 in esophageal squamous cell carcinoma tumors. Expression of CD204 was detected in stromal macrophages in 100 % of cases and was not detected in tumor cells. We have shown that in esophageal cancer, IDO1 is expressed in both stromal and tumor cells. In tumor cells, the expression of IDO1 was found in 44 % of the samples, in stromal cells, IDO1 was expressed in 92 % of cases. No association with clinical and morphological characteristics was observed for CD204 in stromal cells and IDO1 in tumor cells. For IDO1 expressed in stromal cells, an association with the stage of the disease (p = 0.0450) and the presence of regional metastases (p = 0.0279) was observed. Survival analysis showed that CD204 is a marker of a favorable prognosis for esophageal cancer (hazard ratio 0.455, p = 0.0419).Conclusion. This study has shown that the expression of IDO1 in the tumor stroma is associated with more favorable clinical characteristics. It has also been shown that an increased content of CD204+ macrophages is a marker of a good prognosis for esophageal cancer.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. Π Π°ΠΊ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° Π½Π°Ρ
ΠΎΠ΄ΠΈΡΡΡ Π½Π° 6βΠΌ ΠΌΠ΅ΡΡΠ΅ ΠΏΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»ΡΠΌ ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΠΈ ΡΡΠ΅Π΄ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΠΉ. ΠΠ»Ρ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠ΅Ρ
Π°Π½ΠΈΠ·ΠΌΠΎΠ² Π΅Π³ΠΎ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎ ΠΈΠ·ΡΡΠ°ΡΡ Π½Π΅ ΡΠΎΠ»ΡΠΊΠΎ Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠ΅ ΠΊΠ»Π΅ΡΠΊΠΈ, Π½ΠΎ ΠΈ ΠΊΠ»Π΅ΡΠΊΠΈ ΠΌΠΈΠΊΡΠΎΠΎΠΊΡΡΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ. Π Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΠ΅ ΠΌΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π»ΠΈ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΈ, Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Ρ ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ, ΠΈ ΠΈΡ
ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΡΠ΅Π½ΠΎΡΠΈΠΏΡ, ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΡ ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Π½ΡΠΉ Π±Π΅Π»ΠΎΠΊ, ΠΈΠ½Π΄ΠΎΠ»Π΅Π°ΠΌΠΈΠ½-ΠΏΠΈΡΡΠΎΠ»-2,3βΠ΄ΠΈΠΎΠΊΡΠΈΠ³Π΅Π½Π°Π·Π° (indoleamine 2,3βdioxygenase- 1, IDO1) Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² 1βΠ³ΠΎ ΡΠΈΠΏΠ° ΠΈ ΡΠΊΠ°Π²Π΅Π½Π΄ΠΆΠ΅Ρ-ΡΠ΅ΡΠ΅ΠΏΡΠΎΡ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (CD204) Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠ°ΡΠΊΠ΅ΡΠ° ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² 2βΠ³ΠΎ ΡΠΈΠΏΠ°.Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ β ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ IDO1 ΠΈ CD204 Π² ΠΎΠΏΡΡ
ΠΎΠ»ΡΡ
ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΠ°ΠΊΠ° ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° ΠΈ ΠΎΡΠ΅Π½ΠΊΠ° Π΅Π΅ ΠΏΡΠΎΠ³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ Π·Π½Π°ΡΠΈΠΌΠΎΡΡΠΈ.ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π±ΡΠ»ΠΈ Π²ΠΊΠ»ΡΡΠ΅Π½Ρ ΠΎΠ±ΡΠ°Π·ΡΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅ΠΉ, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΠΎΡ 48 Π±ΠΎΠ»ΡΠ½ΡΡ
ΠΏΠ»ΠΎΡΠΊΠΎΠΊΠ»Π΅ΡΠΎΡΠ½ΡΠΌ ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°. Π‘ ΠΏΠΎΠΌΠΎΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠ³ΠΈΡΡΠΎΡ
ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π° ΠΎΡΠ΅Π½ΠΊΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ CD204 ΠΈ IDO1. ΠΠ½Π°Π»ΠΈΠ· Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΎΡΡΡΠ΅ΡΡΠ²Π»ΡΠ»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΏΠΎΡΡΡΠΎΠ΅Π½ΠΈΡ ΠΊΡΠΈΠ²ΡΡ
Π΄ΠΎΠΆΠΈΡΠΈΡ ΠΏΠΎ ΠΌΠ΅ΡΠΎΠ΄Ρ ΠΠ°ΠΏΠ»Π°Π½Π°βΠΠ°ΠΉΠ΅ΡΠ°. Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΡΡΠΈ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ Π»ΠΎΠ³Π°ΡΠΈΡΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΡΠ°Π½Π³ΠΎΠ²ΠΎΠ³ΠΎ ΠΊΡΠΈΡΠ΅ΡΠΈΡ. Π Π°Π·Π»ΠΈΡΠΈΡ ΡΡΠΈΡΠ°Π»ΠΈΡΡ ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈ Π·Π½Π°ΡΠΈΠΌΡΠΌΠΈ ΠΏΡΠΈ Ρ <0,05.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ CD204 Π±ΡΠ»Π° ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° Π² ΠΌΠ°ΠΊΡΠΎΡΠ°Π³Π°Ρ
ΡΡΡΠΎΠΌΡ Π² 100 % ΠΈΡΡΠ»Π΅Π΄ΡΠ΅ΠΌΡΡ
ΠΎΠ±ΡΠ°Π·ΡΠΎΠ² ΠΈ Π½Π΅ ΠΎΠ±Π½Π°ΡΡΠΆΠ΅Π½Π° Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
. ΠΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° IDO1 ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΠ΅ΡΡΡ ΠΊΠ°ΠΊ Π² ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
(92 % ΠΎΠ±ΡΠ°Π·ΡΠΎΠ²), ΡΠ°ΠΊ ΠΈ Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
(44 % ΠΎΠ±ΡΠ°Π·ΡΠΎΠ²). ΠΠ»Ρ CD204 Π² ΡΡΡΠΎΠΌΠ°Π»ΡΠ½ΡΡ
ΠΈ IDO1 Π² ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΡ
ΠΊΠ»Π΅ΡΠΊΠ°Ρ
Π½Π΅ Π½Π°Π±Π»ΡΠ΄Π°Π»ΠΎΡΡ Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΠΈ Ρ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ Π±ΠΎΠ»ΡΠ½ΡΡ
. ΠΠ»Ρ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π²ΡΡΠ²Π»Π΅Π½Π° Π°ΡΡΠΎΡΠΈΠ°ΡΠΈΡ ΡΠΎ ΡΡΠ°Π΄ΠΈΠ΅ΠΉ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ (p = 0,0450) ΠΈ Π½Π°Π»ΠΈΡΠΈΠ΅ΠΌ ΡΠ΅Π³ΠΈΠΎΠ½Π°ΡΠ½ΡΡ
ΠΌΠ΅ΡΠ°ΡΡΠ°Π·ΠΎΠ² (p = 0,0279). ΠΠ½Π°Π»ΠΈΠ· ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ Π²ΡΠΆΠΈΠ²Π°Π΅ΠΌΠΎΡΡΠΈ ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π», ΡΡΠΎ CD204+ ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠΌ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΠΎΠ³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° ΡΠ°ΠΊΠ° ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π° (ΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΡΠΈΡΠΊΠΎΠ² 0,455, p = 0,0419).ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½Π½ΠΎΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ Π±ΡΠ»ΠΎ ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ IDO1 Π² ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ Π±ΠΎΠ»Π΅Π΅ Π±Π»Π°Π³ΠΎΠΏΡΠΈΡΡΠ½ΡΠΌΠΈ ΠΊΠ»ΠΈΠ½ΠΈΠΊΠΎ-ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ°ΠΌΠΈ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ². Π’Π°ΠΊΠΆΠ΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΠΎΠ΅ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ Π² ΡΡΡΠΎΠΌΠ΅ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ CD204+ ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² ΡΠ»ΡΠΆΠΈΡ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΌ Ρ
ΠΎΡΠΎΡΠ΅Π³ΠΎ ΠΏΡΠΎΠ³Π½ΠΎΠ·Π° Π΄Π»Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
ΡΠ°ΠΊΠΎΠΌ ΠΏΠΈΡΠ΅Π²ΠΎΠ΄Π°